January/February 2012

Total 1-year healthcare costs were not significantly reduced by 2 value-based insurance design programs for diabetic patients, although education appeared to improve quality of care.

Saxagliptin, in combination with metformin, provides a durable, well-tolerated, and cost-effective treatment option for patients with type 2 diabetes mellitus, from a US payer perspective.

Within the last 5 years changes to oncology private practice have led to these clinics aligning themselves with larger entities to maintain their practices.

The Pharmacy & Therapeutics Society has become the Specialty Healthcare Benefits Council (SHBC).

Drug shortages, whether caused by the manufacturers or the FDA, continue to escalate. The federal government has recently begun to address this concern.